Neoplasms

All Conditions

Rare Diseases

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Neuroendocrine Tumor

Neuroepithelioma

Gastrointestinal Agents

All Drugs and Chemicals

Calcium Carbonate

Patients with malignant neuroendocrine tumors

Asher Salmon, M.D., Ph.D.

Hadas Lemberg, PhD

Arik Tzukert, DMD

Benjamin Nisman, PhD

Tamar Peretz, M.D., PhD

Asher Salmon, M.D.

The purpose of this study is to determine whether monitoring of levels of Serological Markers ProGRP, CgA, NSE and Pyruvate Kinase M2 are effective in the Evaluation of Diagnosis, Monitoring Therapeutic Effects and Predicting response to somatostatin analogues in Patients with Malignant Neuroendocrine Tumors.

Assessment of the anatomical spread and disease progression in neuroendocrine tumor patients has become an essential part of disease management, but sometimes in many patients difficult to be measured. Therefore, the evaluation of serum markers could represent a useful tool for monitoring the course of the disease and the response of patients to therapy or palliative treatment.Clinical data considers CgA and NSE as available today blood biomarkers for neuroendocrine tumors.Until now the usefulness of serum ProGRP as a clinical tumor marker has been evaluated mainly in Small Cell Lung Carcinoma, while its role in the management of NE tumors has not been elucidated.Available in the literature limited data suggests that ProGRP may be a potential tumor marker in NE tumors.

Pyruvate kinase type M2 is the key glycolytic regulator in tumor cells.It catalyzes the dephosphorylation of phosphoenolpyruvate to pyruvate with ATP production.The dimeric form of this enzyme (TUM2-PK) has been detected in the blood of patients with different cancers.High TUM2-PK expression was suggested to be an important element of tumor cell metabolism adaptation to an inadequate oxygen and nutrient supply.Recently, it has been shown that somatostatin and its structural analogues pass through cell membrane and actively bind to cytosolic TUM2-PK. In response to this binding TUM2-PK translocates into the nucleus and induce programmed cell death. It is suggested that TUM2-PK enzyme may contribute significantly to response of neuroendocrine tumors to somatostatin analogues.

ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors

Evaluation of Serological Markers ProGRP, CgA, NSE and TUM2-PK in Patients With Malignant Neuroendocrine Tumors

Hadassah Medical Organization

Asher Salmon

Symptoms and General Pathology

Nervous System Diseases

Behaviors and Mental Disorders

Wounds and Injuries

Frailty

Delirium

Cognitive Dysfunction

Brain Injuries

Postoperative Cognitive Complications

Emergence Delirium

Confusion

Neurobehavioral Manifestations

Neurologic Manifestations

Neurocognitive Disorders

Mental Disorders

Psychotic Disorders

Cognition Disorders

Postoperative Complications

Central Nervous System Depressants

Anesthetics

Elective urologic oncology surgeries such as radical nephrectomy, radical cystectomy, radical prostatectomy in older than 65 years

Patients are monitored by near infrared spectroscopy before anesthesia induction until end of the operation. Graphical presentation of cerebral oxygenation during surgery evaluated by INVOS Analytics Tool Version 1.2.

Near Infrared Spectroscopy (NIRS)

Blood samples are obtained before and after surgery. S-100, Neuron specific enolase (NSE), Interleukin-6 (IL-6), High Mobility Group Box Protein (HMGB-1) are going to be studied by ELISA method after data collection process end.

Blood sample

ACE-III is administered to study participants one day before surgery, 1 week after surgery, and three months after surgery to diagnose postoperative cognitive dysfunction.

Addenbrooke Cognitive Examination III (ACE-III)

Confusion Assessment Method is administered to study participants in postoperative recovery room to diagnose postoperative delirium.

Confusion Assessment Method

Emre Şentürk, MD

Meltem Savran Karadeniz, Assoc.Prof.

Meltem Savran Karadeniz, Assoc. Prof.

Postoperative cognitive changes are more common in elderly patients, which can result in poor quality of life, loss of workforce, disability, early retirement, physical-social dependence, increased health care cost and premature mortality. Postoperative cognitive complications are also quite common in extensive oncological surgeries. In this study, our aim is to evaluate the relationship between the development of postoperative cognitive dysfunction (POCD) in geriatric urologic oncology patients with brain injury and inflammatory markers \[S100 β, neuron specific enolase (NSE), interleukin 6 (IL-6) and high mobility group box-1 (HMGB-1 protein)\].

The incidence of POCD changes by age group, type of surgery, testing neuropsychological tests, timing of tests, and the method used for diagnosis. In non-cardiac surgery over the age of 60; the incidence of POCD was 26% in the postoperative 1st week and 10% in the postoperative 3rd month. Although old age is an important risk factor, POCD incidence of up to 36.6% has been reported in a younger period. Major cancer surgery is an important risk factor for development of POCD.

Numerous biomarkers such as; S100β, NSE, Human IL-6, HMGB-1 protein; have been evaluated in studies to determine the diagnosis, prognosis, stage and treatment of POCD.

In this study, our aim is to evaluate the relationship between the development of postoperative cognitive dysfunction (POCD) in geriatric urologic oncology patients with brain injury and inflammatory markers. (S100β, NSE, Human IL-6 and HMGB-1 protein).The hypothesis of our study is that postoperative brain injury and inflammatory markers (S100β, NSE, Human IL-6 and HMGB-1 protein) will be higher in patients who develop POCD compared to patients who do not develop POCD in geriatric urologic oncology surgery.

Blood samples are collected from study participants after anesthesia induction and after the end of the operation.

Postoperative Cognitive Dysfunction in Elderly Urologic Oncology Patients (POCD)

Evaluation of the Relationship Between Postoperative Cognitive Dysfunction and Brain Injury Biomarkers In Geriatric Urologic Oncology Patients

Test score is between 0-100. 100 is the best point and 0 is the worst point in the test. The test has five cognitive domains including attention, memory, language, visuospatial function, and verbal fluency. Patients who score less than 88 in preoperative tests will be diagnosed with mild cognitive impairment.

POCD is diagnosed by 1 standard deviation decrease from the preoperative test scores.

Blood S 100β concentration is determined by an enzyme-linked immunosorbent assay kit.

HMGB1 concentration is determined by an enzyme-linked immunosorbent assay kit.

h-NSE concentration is determined by an enzyme-linked immunosorbent assay kit.

Blood IL-6 concentration is determined by an enzyme-linked immunosorbent assay kit.

Postoperative delirium is diagnosed by confusion assessment method.

Cerebral hypoxia is defined as reduction of regional oxygen saturation by 10 % from baseline before surgery.

Stroke, transient ischemic attack, arrhythmia, heart failure, myocardial injury, respiratory failure, pneumonia, ileus, acute kidney injury, prolonged length of stay, mortality.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors	NCT00851604	Neuroendocrine ...		18 Years - 90 Years	Hadassah Medical Organization
ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors	NCT00851604	Neuroendocrine ...		18 Years - 90 Years	Hadassah Medical Organization
Postoperative Cognitive Dysfunction in Elderly Urologic Oncology Patients (POCD)	NCT04837391	Postoperative C... Postoperative D... Frailty	Near Infrared S... Blood sample Addenbrooke Cog... Confusion Asses...	65 Years -	Istanbul University
ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors	NCT00851604	Neuroendocrine ...		18 Years - 90 Years	Hadassah Medical Organization

Spots Global Cancer Trial Database for nse

Every month we try and update this database with for nse cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for nse

Every month we try and update this database with for nse cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for nse cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.